Immuneering Corporation (IMRX) Return on equity 2021–2023
Immuneering Corporation (IMRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-59.0%FY2023 · since FY2021: -21.5% → -59.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -59.0% | -13.1 pp |
| FY2022 | -46.0% | -24.5 pp |
| FY2021 | -21.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice